Opinion|Videos|July 23, 2024
Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC
A panel of experts describe the key challenges and unmet needs for patients with newly diagnosed mNSCLC.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Describe the key challenges and unmet needs for patients with newly diagnosed mNSCLC lacking targetable driver mutations.
- What proportion of mNSCLC patients harbor drivers like EGFR, ALK, etc?
- How does the presence of these mutations impact prognosis and guide first-line treatment?
- What are the unique challenges and unmet needs for specific subgroups of mNSCLC patients without drivers, such as those with without PD-L1 expression, squamous histology, or brain metastases?
- Beyond PD-L1, what factors do you consider when selecting first-line treatment in the driver-negative setting?
Advertisement
Related to this article
Leaders from Boehringer Ingelheim, Incyte, Pfizer, and Takeda told the audience at Patient-Centered Oncology Care® that artificial intelligence (AI) is compressing discovery timelines, but that gaps in testing, data, and community access still decide which patients benefit.
Many patients who stop a GLP-1 RA regain weight. How plans can measure adherence when cash-pay fills go unseen.
Invivyd presented preclinical IDWeek 2026 data on VMS063, an investigational antibody that neutralized B3 and D8 measles variants in vitro.
In more than 250,000 adults with prediabetes and obesity, GLP-1 users had lower risks of type 2 diabetes, death, and cardiovascular events.
Sphingolipid profiles in plasma and breath condensate differed between IPF and f-HP and tracked with disease severity, CHEST 2026 data show.
The FDA granted accelerated approval to the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP).
In nearly 443,000 US adults, both low-frequency and heavy cannabis use were linked to higher odds of cardiovascular disease, led by stroke.
Clinicians separate idiopathic hypersomnia from depression-related sleepiness and interpret real-world and trial data for better outcomes.
Advertisement
Advertisement
Trending on AJMC
1
Enlicitide LDL-C Lowering Holds Across Risk Levels Up to 2 Years
2
Occasional Cannabis Use Linked to 40% Higher Odds of Stroke
3
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
4
FDA Approves First Plasmid DNA-Based Immunotherapy for Adults With RRP
5